Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Infectious Disease Implementation Research

The Infectious Disease Implementation Research Team is a multi-disciplinary group researching the best way to implement infectious disease prevention and treatment strategies to improve the wellbeing of children and teenagers.

The Infectious Disease Implementation Research team is developing and implementing better ways to observe and evaluate the effectiveness of public health programs, including optimising treatment for both acute and complex diseases and  exploring new strategies through disease modelling and analytics - providing real-world results that are immediately applicable.

The team uses a range of methods to conduct their research, including pragmatic and adaptive clinical trials, observational comparative effectiveness studies and data linkage studies, causal network and transmission modelling and learning health systems research.

Focusing on common and serious childhood infections such as gastroenteritis, serious bacterial infections and cystic fibrosis exacerbations, the Implementation Research team are looking at new and innovative clinical trial methods and analytic approaches for evaluating treatments. This includes examining their effectiveness by embedding research in the clinical settings they are intended to be used, and working on projects to gauge efficacy of new and existing preventions and treatments in a way that has never been done before in Australia.

Collaborating widely, the team works with clinicians, policy makers, epidemiologists, statisticians and importantly, community members, to help ensure their research is efficient, sustainable and responsive to clinical, community and policy needs. The team also work in close collaboration with other research groups around Australia, including the University of Sydney’s Health and Clinical Analytics Team, particularly to support many studies that are underway at sites outside of Western Australia.

Team Highlights

In 2019, the Implementation Reseatch team were successful in securing major funding for:

  • Randomised controlled trial of mixed whole-cell/acellular pertussis vaccination versus acellular-only vaccination of infants (GNT1158722, NHMRC project grant, 2019-2023, $3.9million)
  • Adaptive Trial of Messaging to Improve Vaccine Coverage (AuTOMATIC), (Ramaciotti Health investment grant, 2020-22, $280,000)
  • Collaborative project 'Better health through better trials: a national network to develop and implement innovative clinical trials methodology'. (GNT1171422, NHMRC Centres of Research Excellence, 2019-2024, $2.4million)

The Implementation Research team shared its ideas and results to several audiences across a range of mediums, including:

  • providing educational seminars to students, researchers and clinical trialists throughout Australia
  • launching the Adaptive Health Intelligence website to optimise further collaborative opportunities
  • holding consumer workshops for individuals living with cystic fibrosis and hepatitis C.

Team leader

Professor Tom Snelling
Professor Tom Snelling

BMBS DTMH GDipClinEpid PhD FRACP

Head, Infectious Disease Implementation Research

Team members (15)

Sarah Brazier
Sarah Brazier

BSc (Hons), MBA

Senior Program Manager, Wesfarmers Centre of Vaccines & Infectious Diseases

Julie Marsh

Julie Marsh

Senior Biostatistician

Michael Dymock

Michael Dymock

Biostatistician

Nelly Newall

Nelly Newall

Clinical Trial Co-ordinator

Jessica Ramsay

Jessica Ramsay

Clinical Research Co-ordinator

Reena D’Souza

Reena D’Souza

Project Manager

Kylie Rogers

Kylie Rogers

Data Manager

Mitch Messer

Mitch Messer

Consumer Advisor

Charlie McLeod

Charlie McLeod

Clinical Research Officer

Evelyn Tay

Evelyn Tay

Biostatistician

Ariel Mace

Ariel Mace

PhD Student

Carly McCallum

Carly McCallum

Clinical Research Manager

Ada Parry

Ada Parry

Cultural Advisor

Edward Pan

Edward Pan

Statistical Programmer

Gladymar Perez

Gladymar Perez

PhD Student

Infectious Disease Implementation Research

Resources

Reports and Findings

Show all

Statistical considerations for the platform trial in COVID-19 vaccine priming and boosting

The Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies against severe acute respiratory syndrome coronavirus 2 and its variants, specific for the Australian context.

Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial

Immunocompromised hosts experience more breakthrough infections and worse clinical outcomes following infection with COVID-19 than immunocompetent people. Prophylactic monoclonal antibody therapies can be challenging to access, and escape variants emerge rapidly. Immunity conferred through vaccination remains a central prevention strategy for COVID-19.

Evaluation of Pediatric HIV Postexposure Prophylaxis Guideline Following Child Sexual Assault in Western Australia

HIV postexposure prophylaxis (PEP) following child sexual assault (CSA) is recommended in select cases. High rates of poor adherence to PEP are reported. We evaluated adherence to the recommended management of children following CSA at the tertiary pediatric facility in Western Australia and compared our approach with international guidelines.

Does adjunctive clindamycin have a role in Staphylococcus aureus bacteremia? A protocol for the adjunctive treatment domain of the S. aureus Network Adaptive Platform (SNAP) randomized controlled trial

The use of adjunctive antibiotics directed against exotoxin production in Staphylococcus aureus bacteremia (SAB) is widespread, and is recommended in many guidelines, but there is limited evidence underpinning this.

Show all